ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01335165
- Locations
- 🇵🇱
University Clinical Centre, Dębinki 7, Gdańsk, Poland
🇨🇿Institute of Hematology and Blood Transfusion / Institut Hematologie a krevní transfuze, U nemocnice 1, Prague 2, Czech Republic
🇮🇹Federico II University of Naples, Via Pansini 5, Naples, Italy
Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01307098
Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01205152
- Locations
- 🇺🇸
Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸St. Vincent Hospital, Green Bay, Wisconsin, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01203826
- Locations
- 🇺🇸
Shriners Hospital for Children, Saint Louis, Missouri, United States
🇨🇦Children's Hospital Health Sciences Centre, Winnipeg, Manitoba, Canada
E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT01194804
An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT01194973
Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes
Completed
- Conditions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2010-09-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 5580
- Registration Number
- NCT01192425
Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01192399
An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01193348
Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT01180790
- Locations
- 🇧🇪
Clinical Trial Site, Gent, Oost-Vlaanderen, Belgium
© Copyright 2024. All Rights Reserved by MedPath